Drug Trial Radar · NCT07846722
Esmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Dec 1, 2026
Study completion Feb 1, 2027
Sponsor
- Lead sponsor
- Vasiliki SamartziAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 29, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate and compare the effects of a continuous infusion of low-dose esmolol and dexmedetomidine versus placebo on intraoperative and postoperative opioid consumption and analgesic efficacy in patients undergoing laparoscopic hysterectomy.
Conditions
- Pain, Acute Post-Operative
- Dexmedetomidine
- Analgesia
- Esmolol
- Nociceptive Pain
- Laparoscopic Hysterectomy
Interventions
Esmolol hydrochlorideDrug
In the esmolol group, patients will receive a loading dose of esmolol administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative esmolol infusion.
DexmedetomidineDrug
In the dexmedetomidine group, patients will receive a loading dose of dexmedetomidine administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative dexmedetomidine infusion.
Normal (0.9%) salineDrug
In the placebo group, patients will receive a loading dose of normal saline administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative normal saline infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total postoperative opioid consumptionTime frame: First 24 hours postoperatively
- PCA utilization parametersTime frame: First 24 hours postoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
"Alexandra" General Hospital
Athens, Greece · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.